According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

The FDA said in a statement that it had determined that one of the two approved vaccines, Ixchiq (Valneva SE), which contains a live, weakened version of the chikungunya virus, was responsible for 21 ...

US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

FDA suspends Ixchiq license, raising regulatory risks for Valneva. Key vaccines anchor revenue, but valuation concerns emerge ...

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

Reports of side effects have prompted reviews in particular over its use in older patients. Read more at straitstimes.com.

Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

US health authorities have suspended the licence of the Ixchiq vaccine, used against the mosquito-borne chikungunya virus, ...

The U.S. Food and Drug Administration (USFDA) has suspended the biologics license of Ixchiq (Chikungunya Vaccine, Live), ...

The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.

Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...